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Executive Summary 
Glaucoma is a family of diseases that afflicts 65 million people worldwide. Primary open 
angle  glaucoma  is  the  most  common  type  of  glaucoma.  This  is  characterized  by  increased 
intraocular pressure (IOP) within the eye that results in vision loss. Current therapeutic drugs 
include Timolol and Brimonidine which studies have shown to yield a greater decrease in IOP 
through  combined  drug  therapy  than  monotherapy.  In  2007  Combigan,  an  eye  drop  that 
combines the therapeutic effects of Timolol and Brimonidine, was approved for use by the FDA. 
This  project  proposes  a  method  for  treating  glaucoma  through  delivery  of  Combigan  via  a 
contact lens through which the drugs will diffuse into the eye over a period of time.  
We modeled the diffusion of two drugs, Timolol and Brimonidine, through four layers of 
the human eye. The drug was delivered via a contact lens, so that the concentration of drug in the 
aqueous humor would remain above the minimum effective dosage for longer than if it were 
delivered via eye drops. We calculated the concentration of each drug in all layers of the eye for 
12 hours. Our model was verified by experimental data in the published literature. Our model 
failed to deliver solely Timolol or Brimonidine for 12 hours, which was our goal, but still was 
significantly more effective than eye drops. However, throughout the twelve hours there was at 
least  one  drug  in  the  aqueous  humor  and  since  both  drugs  lower  IOP  through  different 
mechanisms our model did deliver treat the glaucoma for the whole twelve hours. If it were 
possible to lower the diffusivity of Timolol through the stroma, this would allow for Timolol to 
remain longer in the aqueous humor thus making the contacts better at treating glaucoma.   
A  sensitivity  analysis  demonstrated  that  our  model  was  robust  in  the  tear  film  and 
relatively robust in the contact lens. However, the model was particularly sensitive to diffusivity 
in the stroma layer, as the stroma acts as the final barrier to aqueous humoral penetration and is 
quite thick. Brimonidine was delivered at a more constant rate, but at a lower concentration than 
Timolol. It also took six times longer than Timolol to reach its maximum concentration in the 
aqueous humor. Drug delivery via contact lenses is a feasible technology as more effective than 
eye drops, but can be improved by designing a time-release drug that diffuses more slowly. 
Further research needs to be conducted in order to investigate the practicality of this method. 
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Introduction 
Glaucoma is a family of diseases that afflicts 65 million people worldwide (2). The most 
common type of glaucoma is primary open angle glaucoma (POAG), which affects 3 million 
Americans (1). This type of disease is characterized by increased intraocular pressure (IOP) 
within the eye that results in optic nerve damage and subsequent vision loss (1). The increased 
IOP (normal range 12-22mmHg) results from a malfunctioning drainage system in the form of 
canals around the iris (1). A healthy drainage system facilitates the uptake of aqueous humor into 
the bloodstream (1, Figure 1). However in the case of POAG, the inner drainage canals become 
clogged, which results in fluid and pressure build-up that further damage the sensitive meshwork 
over  time  (1,  Figure).  Since  POAG  progresses  slowly  over  years,  an  early  diagnosis  and 
treatment  helps  impede  vision  loss.  Available  treatments  include  medicines,  laser 
trabeculoplasty, conventional surgery or a combination of the three (3). However, current trends 
show that fewer people are opting for invasive surgery as improved early detection methods for 
glaucoma enable patients to control IOP through medications (4). Treating glaucoma through 
drugs poses advantages such as being non-invasive with limited side effects (3).  
 
 
 
 
 
 
 
Figure 1. Normal fluid drainage in the human eye (3). 
There are currently many drugs on the market for patients to choose from. Two of the 
most widespread and effective of these drugs are Timolol Maleate and Brimonidine Tartrate. 
Timolol is a non-selective beta-blocker that reduces the production of aqueous humor (8). Over 
time, it has been shown to reduce IOP by 26 to 38% (8). Meanwhile, Brimonidine is a selective 
alpha adrenergic receptor agonist that reduces IOP by reducing aqueous humor production and 
increasing uveoscleral outflow (9). Studies have shown exciting results that that a combined 
treatment of Timolol and Brimonidine yields a greater decrease in IOP than monotherapy (6, 7). 
In  2007  Combigan,  an  eye  drop  that  combines  the  therapeutic  effects  of  Timolol  and   5 
Brimonidine, was approved for use by the FDA (5). This project proposes to model the delivery 
of Combigan to the eye via an alternative method, a contact lens. 
 
Schematic 
 
Figure 2. The contact lens and different layers of the human eye. 
 
Design Objectives 
  Create a model of the eye to simulate drug diffusion 
  Compare our results to experimental data to verify model. 
  Introduce realistic complications to the model to better simulate a human eye. 
For  this  project,  we  plan  to  model  the  diffusion  of  two  drugs,  Timolol  Maleate  and 
Brimonidine Tartrate, through a contact lens and the top four layers of the human eye. The eye 
will be modeled as a rectangular 2-dimensional region comprised of the contact lens, the tear 
film,  the  epithelium,  the  stroma,  and  the  aqueous  humor.  Diffusion  is  primarily,  in  the  z 
direction. For boundary conditions, all boundaries will be insulating except for the bottom of the 
aqueous humor region, which will have zero drug concentration. Both drugs will have an initial 
concentration only in the contact lens region. The process of diffusion will be modeled over a 
time course of 12 hours.   6 
 
Results and Discussion 
We modeled the diffusion of two drugs, Timolol and Brimonidine, through a contact lens 
and four layers of the eye. In our model, both drugs are present in the contact lens at the same 
time; thus both drugs diffuse at the same time. We have not found any literature claiming that the 
drugs react with each outer, so our model assumes that there is no cross-reactions. We used the 
parameters  displayed  in  Appendix  A  for  initial  concentrations  and  diffusivities.  The  initial 
concentrations were based on the concentration of drug in Combigan brand eye drops. We ran 
the simulation for 12 hours (43200 seconds). See Appendices B for details on calculations and 
time-stepping. We also modeled a scenario where no contact lens was used, but drug was applied 
via an eye drop, so that the same total mass of drug is applied. In this model, all of the same 
parameters were used, except the boundary at the top of the top of the tear film was the initial 
concentration of the drug instead of insulated.  
Figure 3, left graph shows a profile of the average concentration of each drug in the 
aqueous humor over 12 hours. Figure 3 right graph shows the concentrations of each drug at the 
boundary between the stroma and aqueous humor over time. The maximum concentration of 
Timolol was 5.66*10
-8 mol/cm
3, and was reached at 28 minutes, 20 seconds. The concentration 
rose sharply over the first 30 minutes, and then decayed much more slowly, remaining above 10 
g/mL  for  120  minutes.  By  320  minutes,  the  concentration  was  less  than  1  g/mL.  The 
maximum  concentration  of  Brimonidine  was  7.55*10
-9  mol/cm
3,  and  was  reached  at  213.2 
minutes. The concentration of Brimonidine increased and decayed at a much slower rate than 
Timolol. Both figures show that there is not any significant drug concentration in the aqueous 
humor at the end of 12 hours. 
Figure 3 shows that our contact model cannot keep the concentration of either drug in the 
eye high enough for 12 hours. One way to improve this could be to modify the drug to diffuse 
slower. In fact, in an early simulation trial, a diffusivity value was entered erroneously as two 
orders of magnitude too small. In this trial, the concentration of the drugs in the aqueous humor 
never decayed. This prevented our results from being confirmed by experimental data, but is 
much better from a design perspective.   7 
   
Figure 3: (Left) Average Concentration of each drug in the aqueous humor over time. (Right) 
Concentration of each drug at the boundary between the stroma and the aqueous humor over 
time. 
 
In Figure 3, the average results confirm the single-point results. Timolol diffuses much 
more  quickly  than  the  Brimonidine.  The  Timolol  reaches  its  maximum  concentration  at  27 
minutes,  20  seconds.  The  Brimonidine  reaches  its  maximum  concentration  at  3  hours,  35 
minutes, 10 seconds.  
To  test  the  accuracy  of  these  results,  we  did  an  accuracy  check  against  published 
experimental data. We were unable to find literature exactly matching our model. However, in 
2006, Wei et al experimentally measured Timolol concentration in the aqueous humor of rabbits 
after given eye drops. After adjusting the initial concentrations, we were able to compare our 
results to Wei’s results. Figure 4 (left) shows Wei’s results, the right graph shows our eye drop 
model’s results for the concentration of the drugs at the same point in the aqueous humor.   
   8 
   
Figure 4: (Left)Results from Wei, et al.  Pharmacokinetics of Timolol in aqueous humor sampled 
by microdialysis after topical administration of thermosetting gels. (Right) Concentration of 
Timolol in the aqueous humor when delivered via eye drops. 
 
As shown in Figure 4 our results match the results of Wei. Our peak value is higher, but 
this could be due to the fact that our parameters were for the human eye, not the rabbit eye. Our 
graph  shows  the  proper  shape,  with  a  rapid  increase  in  concentration  followed  by  a  slower 
decline. In both models, concentration was negligible by 150 minutes. 
The model in figure 6 can also be used to compare contact lenses and eye drops as 
delivery vectors for the drug. In the eye drop model, the concentration of Timolol reached 1141 
g/mL in only 11 minutes, 40 seconds. However, it decayed rapidly. It also dropped below 10 
g/mL at 120 minutes, and dropped below 1  g/mL after only 172 minutes. Thus, although our 
contact lens failed to maintain aqueous humor concentration for 12 hours, it still maintained 
aqueous humor concentration for significantly longer than an eye drop would. 
To determine the extent of mesh error, we performed a mesh convergence analysis. We 
ran our simulation under circumstances of increasingly fine mesh. See Table 1 for the mesh 
dimensions used. Basically, the number of nodes remained constant in the r direction, and was 
consistently doubled in the z direction, and then the model was simulated for the full 12 hours. 
We then had COMSOL integrate to solve for the total amount of Timolol in the aqueous humor 
(in  mol),  as  well  as  the  total  volume  of  the  aqueous  humor  (in  cm
3).  These  allowed  us  to 
calculate the average concentration of Timolol, and plot the change in average concentration as a 
function of the number of elements in the model.   9 
Table 1: Mesh properties.  All regions have 5 nodes in the r direction. 
  Below are the number of nodes in the z direction for each region 
region  6400 nodes total 
Contact  160 
Tear Film  80 
Epithelium  160 
Stroma  240 
Aqueous Humor  640 
 
Figure 5 displays the results of the convergence analysis for Timolol. As the number of 
elements increases, the concentration of Timolol in the aqueous humor appears to approach an 
asymptote. At 6400 elements, the concentration might still be increasing with increased mesh 
size; however the change between 3200 and 6400 is 5.5 * 10
-16 mol/cm
3. We presumed the 
change in solution with additional computational elements would be increasingly negligible, and 
so for the sake of computing time, did not use more than 6400 elements for any solution. 
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Figure 5: Mesh convergence analysis of Timolol in the aqueous humor. 
 
Sensitivity Analysis 
We performed a sensitivity analysis on the model by varying diffusivity of each drug 
component Timolol and Brimonidine in three regions (the contact lens, tear film, and stroma) 
using  COMSOL,  while  keeping  all  other  parameters  constant.  Increasing  or  decreasing  the 
normal diffusivity parameter in each region by an order of a magnitude allowed us to determine 
the effect of changes in diffusivity in each region on the final drug concentration in the aqueous 
humor. This variation in diffusivity allowed us to gage the sensitivity of our model to such a 
range  in  diffusivity  values.  Figures  6  and  7  below  are  two  summary  plots  for  Timolol  and 
Brimonidine  that  display  the  results  of  the  sensitivity  analysis.  Figures  14-19,  located  in   10 
Appendix C displays the results of diffusivity variation on drug concentration profile in the 
aqueous over a 12-hour period.  
   
Figure 6: (Left) shows the sensitivity analysis of Timolol in regards to time to peak 
concentration. (Right) Shows the sensitivity analysis of Timolol in regards to peak concentration. 
 
Notice in Figure 6 that changing the diffusivity values in the tear film by one order of 
magnitude  in  either  direction  barely  changes  the  model.  Although,  changing  the  stroma 
diffusivity values drastically varied the results in regards to both time to peak concentration and 
peak concentration. 
 
 
Figure 7: (Left) Shows the sensitivity analysis of Brimonidine in regards to time to peak 
concentration. (Right) Shows the sensitivity analysis of Brimonidine in regards to peak 
concentration. 
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Notice that in Figure 7 the same effects are shown as in Figure 6. The tear film is the least 
sensitive but the stroma is the most sensitive parameter. 
The concentration profiles for Timolol at three different diffusivities in the contact lens, 
tear film, and stroma regions are displayed in Figures 14-16. Figures 14 and 16 clearly show a 
direct correlation between the magnitude of the diffusivity value and the peak concentration of 
Timolol during the 12-hour data collection period. For instance, the normal diffusivity value for 
Timolol diffusivity across the contact lens region is 9.9E-9 cm
2/s. As shown in Figure 14, the 
normal diffusivity resulted in a peak drug concentration of 2.96E-9 moles/cm
3, while increasing 
diffusivity to 9.9E-8 cm
2/s resulted in a peak drug concentration of more than two times that 
value, 6.61E-8 cm
2/s to be exact. Furthermore, decreasing the normal diffusivity in the contact 
lens resulted in a decrease in the peak drug concentration, which is 9.81E-9 moles/cm
3.This 
general  trend  of  a  direct  correlation  between  diffusivity  in  the  region  and  peak  drug 
concentration is also observed in the stroma region (see Figure 16). In addition, this trend is also 
observed in the concentration profile for Brimonidine in Figure 17. Figures 15 and 18 show the 
concentration profile of Timolol and Brimonidine at various diffusivities across the tear film 
region.  In  each  figure,  the  concentration  curves  overlap  each  other,  implying  that  varying 
diffusivity across the tear film has very little effect on the concentration of each drug component 
in the aqueous humor. This result is logical since the tear film region is relatively thin (0.007mm) 
when compared with the contact lens (0.105mm) and the stroma (0.45mm), thus making any 
inhibitory or facilitating contributions to diffusivity minimal.  
The results of our sensitivity analysis are summarized in Figures 20-25, also located in 
Appendix C. In these plots, we mapped out the relationship between the varied diffusivities 
versus the resulting peak drug concentration in the aqueous humor. After varying the diffusivities 
of Timolol and Brimonidine by plus or minus one order of magnitude, we observed where our 
model was most sensitive to the biological parameter of diffusivity.  
In particular, the tear film exhibited behavior for both drug diffusivity changes that we 
did not expect to see, but can justify based upon physical principles. In both Figures 22 and 25, 
we saw a plateau develop in the curve, a region in which there is virtually no change in peak 
concentration in the aqueous humor with respect to changes in drug diffusivity in the tear film. 
This observation fits with the trends observed in Figures 15 and 18, in which the raw data plots 
showed little to no variation in drug concentration versus time. We concluded that because the   12 
tear film is such a thin layer in the eye and consequently represents a small portion of the depth 
that  the  drug  components must  diffuse  through  in  our  model,  even  drastically  increasing  or 
decreasing the diffusivity of both drugs in that layer has almost no effect overall on the resulting 
drug concentrations in the aqueous humor. As the drug concentrations in the aqueous humor are 
the only area of interest to us in terms of the goal of our project, the treatment of glaucoma, we 
can say that drug diffusivity in the tear film is not as much of a limiting factor when compared to 
diffusivities elsewhere in the eye. 
The “negligibility factor” that we observed through analysis of peak drug concentration 
versus diffusivity changes in the tear film did not occur, however, in our analyses of the stroma 
and the contact lens. We attribute this to the thickness of the two layers as well as the fact that, in 
particular, the stroma acts as a final barrier to drug access to the aqueous humor. In Figures 20 
and 23, it is shown that the peak concentration of Timolol and Brimonidine in the aqueous 
humor is sensitive to the drug diffusivity in the lens and that these data are related linearly. 
However, the slopes of those lines versus the linear relationships displayed in Figures 21 and 24 
(diffusivity  changes  made  in  the  stroma  layer)  are  significantly  less  in  magnitude.  This  is 
indicative of the stroma acting as a barrier, because diffusivity changes in the final, thick layer 
before the aqueous humor inhibits drug transport, thus impacting the peak concentrations of drug 
achieved in the humor. In Figure 19, this concept is highlighted well by the raw data plot which 
shows that an increase in Brimonidine diffusivity in the stroma significantly increases the peak 
value for concentration in the aqueous humor, but decreasing it below the value used by the 
model decreases the peak concentration.In addition, we looked at the effects of changing the 
initial concentrations of each drug. We varied the initial concentration of each drug in the contact 
lens and observed the change in concentration at the boundary between stroma and aqueous 
humor.    Below,  Figures  8  and  9  show  the  effects  of  increasing  and  decreasing  the  initial 
concentration of each drug by 1 order of magnitude. Increasing the concentration of Timolol 
increases its residence time in the aqueous humor, but not to 12 hours. It is not reasonable to 
increase this concentration anymore; other means must be used if we are to reach 12 hours. 
Brimonidine seems to become a feasible option by simply changing the initial concentration. 
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Figure 8: Change in concentration of Timolol at the aqueous humor boundary with variable 
initial concentration 
 
Notice in Figure 8 that decreasing the amount of Timolol in the system shows the peak is 
reached at a higher value but at around the same time as the other two values of Timolol. 
 
 
Figure 9: Change in concentration of Brimonidine at the aqueous humor boundary with variable 
initial concentration 
 
Notice that in Figure 9, each graph has the same shape but the peak concentration varies 
when changing the initial concentration. 
In a number of trials, the model returned unexpected results. All of these results were 
attributed to incorrect values for various parameters. Initially, the reaction rate of each drug was 
entered as a positive value. In other words, the drugs were being produced in the eye, rather than 
degraded. Later in our trials, we were still getting unexpected results. We discovered that the 
value for diffusivity in the stroma was reported in the literature as 10
-7 cm
2/s, yet our results   14 
would not match experimental data unless we used a significantly faster diffusion rate (10
-5 
cm
2/s). We presume that the reported value is incorrect. 
One way to increase the amount of time that there is a non-zero concentration of Timolol 
in the aqueous humor is to delay the release of the drug from the eye drop. We wanted to model 
a delayed-release drug to observe the effect on aqueous humor concentration. First, we ran the 
simulation as it originally was, and recorded the concentration of Timolol at the bottom of the 
contact  lens.  We  fit  the  concentration  profile  with  a  mathematical  function.  We  made  the 
assumption that, if the drug were delayed-release, it would be released at a lower, but constant 
concentration for some period of time before decaying, which would be described by the same 
function. We created a data file containing an artificial concentration profile that was constant at 
½ our initial concentration for 1 hour, and then decayed as expected, and imported this into 
COMSOL. Assuming that this took into account the action in the contact, we deleted the top sub-
domain of our model, and set this concentration function as the boundary condition for the top of 
the tear film. Figure 10 shows the result. With this model, it takes a long time for the drug to 
build up in the aqueous humor. However, Timolol buildup is more gradual, and once it begins to 
buildup, it does not decay to zero during our time frame. 
 
 
Figure 10: Concentration of timolol at the boundary of the aqueous humor when the drug is 
simulated to be time-released for one hour. 
 
Notice that in Figure 10 that we have a delayed uptake in the drug. Although, with this 
delayed release the concentraion of the drug after reaching its peaks takes longer to decrease.   15 
We considered simulating the effect of blinking on the concentration profile. However, 
Jonathan Cohan et al simulated blinking in a model of oxygen diffusion in the eye, and found 
that there was no effect on the results (28). With this in mind, we omited this complication. 
In an effort to make our model more realistic we modeled the same problem but with a 
curved  geometry.  We  noticed  that  we  get  similar  results.  There  graphs  of concentration  are 
similar but they do not exactly correspond because the area in the curved geometry is greater 
than that of the area in the rectangular geometry. The other factor is that when the simulation is 
run with the curved geometry there is a build-up of drug in the right corner because the drug in 
the lens has nowhere to go, since the bottom boundary is insulated. Thus, between the two 
geometries we have the same shape of a curve and this proves that our assumption to have the 
geometry rectangular is proved. 
    
Figure 11.The graph to the left shows the Brimonidine Concentration at the Aqueous Humor and 
Stroma Interface over time.  The graph to the right shows the same thing but for Timolol. 
 
Notice in Figure 11 that both graphs at the same point in the geometery show similar 
shapes but different concentrations. 
 
Conclusion and Design Recommendations 
We developed a model that accurately models the diffusion of two drugs through the 
outer layers of the eye and into the aqueous humor, and used this to explore the feasibility of   16 
using contact lenses for drug delivery. We discovered that, given the same initial concentration 
dosage of drug, a contact lens can maintain an acceptable concentration of drug in the aqueous 
humor for longer than an eye drop can. The length of time that the contact lens is effective can be 
further improved by delaying the release of the drugs. If it were possible to modify the Timolol 
to diffuse more slowly through the stroma, drug delivery would also be improved. Currently 
however, there always is at least one drug in the aqueous humor, so there is some lowering of 
IOP for the full 12 hours. It is possible that the contact lens needs to be made thicker to be able to 
hold enough drug. If the lens becomes too big to comfortably wear, then it is not useful for vision 
correction or glaucoma treatment. Thus, lens size is a limiting factor on feasibility. Another 
potential limitation is cost. Currently, the contact lenses are one-time use. Continued use of these 
contact lenses could become expensive, especially if the lenses are costly to manufacture. A 
solution to this would be to design the lenses to be “reloadable”. If the lenses could be soaked in 
solution to re-absorb drug, then the contact could be reusable. 
There  are  both  advantages  and  disadvantages  to  using  our  method.  One  obvious 
advantage is the ease of use.  An eye drop user must remember to administer a dose at specific 
times during the day. Because of the rapid decay of drug concentration after a topical dose, eye 
drops must be applied many times a day. It is often difficult to self-administer eye drops, and the 
exact  amount  of  drug  administered  is  never  known.  A  contact  lens  could  be  applied  in  the 
morning, and left all day. The dosage is more reliable, and need not be reapplied many times 
during  the  day.  As  we  have  shown,  there  will  be  a  more  gradual  rise  and  fall  of  drug 
concentration, avoiding the sudden spike and decline in concentration caused by an eye drop. 
Our method of treatment also has its disadvantages. There is potentially a danger of 
mistaking normal contact lenses with medicated ones, administering an unintentional dose. As 
previously mentioned, the cost of a contact lens treatment could be significantly higher than a   17 
topical treatment. Furthermore, as mentioned, the thickness of these lenses could continue to be 
an issue. This brings up other issues, such as oxygen and moisture diffusion into the eye. Overall, 
we would recommend further study before considering this concept feasible for production and 
use. 
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Appendix A.  
Governing Equation 
A
A
AB
A R
z
c
r
c
r
r r
D
dt
c
2
2 1
 
 
Boundary conditions: 
All boundaries are insulated, EXCEPT for the very bottom of the aqueous humor region, which 
is semi-infinite (concentration = 0). 
 
Table 2.  The values we used for each parameter (Datta). The initial concentration was converted 
from what is used in a typical eye drop of Combigan (13). 
 
Parameter Name  Value for Timolol 
Diffusion 
Value for Brimonidine 
Diffusion 
Initial Concentration in contact lens 
(mol/cm
3) 
1.57225 *10
-5  4.52243*10
-6 
Diffusivity in eye drop  9.9 * 10
-9  1 * 10
-9 
Diffusivity in tear film  5 * 10
-5  1 * 10
-5 
Diffusivity in epithelium  6.022*10
-7  1*10
-7 
Diffusivity in Stroma  8.72*10
-7  1*10
-7 
Diffusivity in aqueous humor  5*10
-5  1*10
-5 
Reaction rate in the 
Tear film 
-1*10
-4 * c  -1*10
-4 * c 
Reaction rate in the aqueous humor  -0.003*c  -0.001*c 
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Appendix B 
To implement this problem into COMSOL 3.3 we set up the problem to solve for two diffusion 
problems at the same time.  We used axis-symmetric for the geometry.  We used a transient 
analysis.  In solver parameters, the time we solved for is from 0 to 43200 seconds with a max 10 
second time step and minimum of 0.0010 seconds.  The relative tolerance is 0.001 and the 
absolute tolerance is 0.00010.  These tolerances let COMSOL know how close convergence 
values to allow. We used the Direct (UMFPACK) linear system solver. 
 
 
Mesh 
 
Figure 12.  The mesh that we used for solving the problem. 
We used a rectangular element for the mesh.  Based upon our mesh convergence analysis 
we determined that we needed 6400 elements to maintain accuracy. 
 
Table 3: Mesh properties.  All regions have 5 nodes in the r direction.  Below are the numbers of nodes in the z 
direction for each region 
region  Normal (400 
nodes) 
Fine (800 
nodes) 
Finer (1600 
nodes) 
Finest (3200 
nodes) 
Finest (6400 
nodes) 
12800 
Nodes 
Contact  10  20  40  80  160  320 
Tear Film  5  10  20  40  80  160 
Epithelium  10  20  40  80  160  320 
Stroma  15  30  60  120  240  480 
Aqueous Humor  40  80  160  320  640  1280 
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Appendix C 
COMSOL representation of drug concentration in the eye after a period of 12 hours.  
 
 
 
 
 
 
 
 
 
 
Figure 13: (Left) Concentration of Timolol in the eye after 12 hours. (Right) 
Concentration of Brimonidine in the eye after 12 hours  
 
Sensitivity Analysis Results 
 
Timolol Concentration in Aqueous Humor at Various Diffusivities in 
the Contact Lens
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Figure 14. Timolol concentration in the aqueous humor region for diffusivities 9.9E-8, 
9.9E-9, 9.9E-10 cm
2/s of in the contact lens region.  
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Figure 15. Timolol concentration in the aqueous humor region for diffusivities 5.0E-4, 
5.0E-5, 5.5E-6 cm
2/s of in the tear film region 
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Figure 16. Timolol concentration in the aqueous humor region for diffusivities 8.72E-6, 
8.72E-7, 8.72E-8 cm
2/s of in the stroma region 
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Figure 17. Brimonidine concentration in the aqueous humor region for diffusivities 1.0E-
8, 1.0E-9, 1.0E-10 cm
2/s of in the contact lens region. 
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Figure 18. Brimonidine concentration in the aqueous humor region for diffusivities 1.0E-
4, 1.0E-5, 1.0E-6 cm
2/s of in the tear film region. 
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Figure 19. Brimonidine concentration in the aqueous humor region for diffusivities 1.0E-
6, 1.0E-7, 1.0E-8 cm
2/s of in the stroma region. 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Plot of the peak Timolol concentration in the aqueous humor vs. varying drug 
diffusivity in the contact lens layer. 
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Figure 21: Plot of the peak Timolol concentration in the aqueous humor vs. varying drug 
diffusivity in the stroma layer. 
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Figure 22: Plot of the peak Timolol concentration in the aqueous humor vs. varying drug 
diffusivity in the tear film layer. 
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Figure 23: Plot of the peak Brimonidine concentration in the aqueous humor vs. varying 
drug diffusivity in the contact lens layer 
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Figure 24: Plot of the peak Brimonidine concentration in the aqueous humor vs. varying 
drug diffusivity in the stroma layer. 
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Figure 25: Plot of the peak Brimonidine concentration in the aqueous humor vs. varying 
drug diffusivity in the tear film layer. 
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